NASDAQ:RARX - Ra Pharmaceuticals Stock Price, Forecast & News

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

Ra Pharmaceuticals Inc (NASDAQ:RARX) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.05. The company had revenue of $3 million for the quarter. View Ra Pharmaceuticals' Earnings History.

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ra Pharmaceuticals.

11 brokers have issued 12-month price targets for Ra Pharmaceuticals' stock. Their forecasts range from $42.00 to $49.00. On average, they anticipate Ra Pharmaceuticals' stock price to reach $47.50 in the next year. This suggests a possible upside of 1.6% from the stock's current price. View Analyst Price Targets for Ra Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 11 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ra Pharmaceuticals.

Press coverage about RARX stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ra Pharmaceuticals earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Ra Pharmaceuticals.

Ra Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 7,960,000 shares, an increase of 45.0% from the January 15th total of 5,490,000 shares. Based on an average daily trading volume, of 762,900 shares, the short-interest ratio is currently 10.4 days. Approximately 20.5% of the company's stock are short sold. View Ra Pharmaceuticals' Current Options Chain.

Some companies that are related to Ra Pharmaceuticals include Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Evotec (EVTCY), Global Blood Therapeutics (GBT) and Arrowhead Pharmaceuticals (ARWR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Amarin (AMRN), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), Fate Therapeutics (FATE), Galmed Pharmaceuticals (GLMD), Immunomedics (IMMU), Novavax (NVAX), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

(RARX) raised $75 million in an initial public offering (IPO) on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Ra Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include CNH Partners LLC (4.04%), Magnetar Financial LLC (3.90%), Citigroup Inc. (3.70%), State Street Corp (3.47%), Farallon Capital Management LLC (2.52%) and ARP Americas LP (2.13%). Company insiders that own Ra Pharmaceuticals stock include Alonso Ricardo, Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp, Rajeev M Shah, Ramin Farzaneh-Far and Simon Read. View Institutional Ownership Trends for Ra Pharmaceuticals.

RARX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Eagle Asset Management Inc., Alliancebernstein L.P., UBS Asset Management Americas Inc., UBS Group AG, SG Americas Securities LLC, Rafferty Asset Management LLC and Bank of New York Mellon Corp. Company insiders that have sold Ra Pharmaceuticals company stock in the last year include Alonso Ricardo, Ramin Farzaneh-Far and Simon Read. View Insider Buying and Selling for Ra Pharmaceuticals.

RARX stock was bought by a variety of institutional investors in the last quarter, including CNH Partners LLC, Magnetar Financial LLC, Citigroup Inc., Farallon Capital Management LLC, ARP Americas LP, Gabelli Funds LLC, Renaissance Technologies LLC and Credit Suisse AG. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RARX stock can currently be purchased for approximately $46.74.

Ra Pharmaceuticals has a market capitalization of $2.20 billion and generates $2.50 million in revenue each year. The company earns $-64,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe.View Additional Information About Ra Pharmaceuticals.

The official website for Ra Pharmaceuticals is http://www.rapharma.com/.

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]